Galena expands patient population in NeuVax BC trial

cp418

http://seekingalpha.com/news/2393926-galena-expand...

Galena expands patient population in NeuVax breast cancer trial

JohnSmith

cp418, I'd like to expand on your post.

Galena is developing peptide vaccine (off-the-shelf) cancer immunotherapies, which address major patient populations of cancer survivors to prevent recurrence of their cancers. These therapies work by harnessing the patient's own immune system to seek out and attack any residual cancer cells. Using peptide immunogens has many clinical advantages, including an excellent safety profile, as these drugs lack the toxicities typical of most cancer therapies. They also evoke long-lasting protection through immune system activation and convenient mode of delivery. Their peptide vaccines are delivered with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF).

"NeuVax" (nelipepimut-S or E75) is Galena's lead immunotherapy product candidate. For those that like details, check out the Galena website.

It targets HER+ cohort.

Current NeuVax Trials:
1. PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 Expression with NeuVax Treatment [International, 700 patient, Phase III trial, with primary outcome measure in April 2018]
2. NeuVax + trastuzumab, HER2 1+ 2+
3. NeuVax + trastuzumab, HER2 3+
4. Gastric Cancer